
It’s a pivotal moment for the MedImmune spinout, which has put the fate of its first prospective product in regulators’ hands.

It’s a pivotal moment for the MedImmune spinout, which has put the fate of its first prospective product in regulators’ hands.

Biotech is booming across the country, especially in the top biotech clusters like Boston, San Francisco, New York and in the BioHealth Capital Region (BHCR). The global biotechnology market is expected to reach $775.2 billion by 2024 at a compound annual growth rate of 9.9 percent.

Boosted by new research and development positions, Massachusetts last year experienced the fastest rate of biopharma job growth in a decade, according to a report released Tuesday from state trade group MassBio.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|

The agreement is intended to create a system for children with rare and complex health conditions.

In support of the U.S. government’s policy to maintain a stockpile to be able to protect every American from smallpox, Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract award by the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) valued at approximately $2 billion over 10 years for the continued supply of ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) into the U.S. Strategic National Stockpile (SNS). The actual number of ACAM2000 doses to be procured is dependent on certain timing and tiered-pricing terms that are subject to the discretion of ASPR. ACAM2000 vaccine is the only vaccine licensed by the

With multiple brand new spec lab/ office suites and numerous shared amenities, 704 Quince Orchard promises to be the ‘best in class’ lab building in the I-270 Corridor.

The Maryland Industrial Partnerships program and the Maryland Technology Development Corp. will jointly host a free briefing about how faculty and local businesses can participate in funding programs at Frostburg State University on Sept. 11 at 2 p.m. in the Harold J. Cordts Physical Education Center Hall of Fame Room.

In the past several years, Greater Boston has cemented itself as the global epicenter of life sciences research. According to JLL’s Life Sciences Outlook report, the region consistently ranks in the top tier of U.S. life sciences clusters, with only San Francisco as its main adversary.

AstraZeneca PLC spinout Viela Bio Inc. filed for an IPO of up to $150 million.
Cambridge, U.K.-based AstraZeneca said in February 2018 that its research and development unit, MedImmune LLC, would move out six experimental compounds from its early-stage inflammation and autoimmunity programs to form Viela Bio, an independent biotech company.